Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 15/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 11/20 | 0.42 |
| ▸ | CASP3 | P42574 | 3/20 | 0.42 |
| ▸ | CASP7 | P55210 | 3/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | SIK1 | P57059 | 1/20 | 0.35 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.35 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9106308 | 0.97 | CDK9 (0.42) | CDK9CCNT1CASP3CASP7HPGDS | |
| SCHEMBL9107064 | 0.94 | CDK9 (0.38) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL9105828 | 0.93 | CDK9 (0.40) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL9108991 | 0.93 | CDK9 (0.44) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL9106930 | 0.92 | CDK9 (0.40) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL9108098 | 0.92 | KDM5A (0.36) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL9101641 | 0.91 | CDK9 (0.38) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL9105238 | 0.91 | CDK9 (0.44) | CDK9CCNT1CASP3CASP7CDK1 | |
| SCHEMBL9101976 | 0.91 | CDK9 (0.44) | CDK9CCNT1CASP3CASP7CDK1 | |
| SCHEMBL9101963 | 0.91 | CDK9 (0.44) | CDK9CCNT1CASP3CASP7CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8816085-B2 | Methylpyrrolopyridinecarboxamides | TAKEDA GMBH (DE) | 2014-08-26 | — | — | US | claimed |
| US-20120142633-A1 | METHYLPYRROLOPYRIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-07 | — | — | US | claimed |
| US-8816085-B2 | Methylpyrrolopyridinecarboxamides | TAKEDA GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20120142633-A1 | METHYLPYRROLOPYRIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142633-A1 | METHYLPYRROLOPYRIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | CDK9 1048/4885CCNT1 1888/4885CASP3 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.